Valuation: Nuvectra Corporation

Market Cap 1.7M 1.49M 1.37M 1.27M 2.41M 162M 2.45M 16.41M 6.43M 79.64M 6.38M 6.24M 276M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46.77M -43.13M -39.9M -75.74M -5.1B -77M -516M -202M -2.51B -201M -196M -8.68B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
-0.82%-1.05%-29.14%-11.79% 166B
+0.46%-0.96%-7.43%-4.70% 105B
-2.30%+2.01%+0.77%+56.85% 60.23B
+3.64%-4.34%+45.42%+51.88% 49.17B
+0.19%-4.57%-14.05%-41.43% 41.49B
+1.36%-5.42% - - 34.08B
-1.40%+2.48%-13.96%-44.10% 28.58B
+1.13%-2.21%+58.13%-5.21% 24.99B
-2.15%+3.29%-9.38%+3.10% 20.64B
Average +0.02%+3.07%+3.80%+0.58% 52.99B
Weighted average by Cap. -0.05%+2.11%-6.16%+0.97%

Financials

2017 2018
Net sales 31.84M 27.85M 25.68M 23.76M 45.1M 3.04B 45.86M 308M 121M 1.49B 120M 117M 5.17B 48.83M 42.72M 39.39M 36.45M 69.18M 4.66B 70.34M 472M 185M 2.29B 183M 179M 7.93B
Net income -44.6M -39.02M -35.98M -33.29M -63.19M -4.26B -64.24M -431M -169M -2.09B -167M -164M -7.24B -48.13M -42.1M -38.83M -35.93M -68.19M -4.59B -69.33M -465M -182M -2.26B -181M -177M -7.81B
Net Debt -1.49M -1.3M -1.2M -1.11M -2.11M -142M -2.15M -14.39M -5.64M -69.84M -5.59M -5.47M -242M -55.16M -48.25M -44.5M -41.17M -78.14M -5.26B -79.45M -533M -209M -2.59B -207M -203M -8.96B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock